# A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

> **NCT06147037** · PHASE1 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 70 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Metastatic Colorectal Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Non-small Cell Lung Cancer
- Pancreatic Ductal Adenocarcinoma
- Gastric Cancer
- Renal Cell Carcinoma

## Interventions

- **DRUG:** FPI-2053
- **DRUG:** [111In]-FPI-2107
- **DRUG:** [225Ac]-FPI-2068

## Key facts

- **NCT ID:** NCT06147037
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-31
- **Primary completion:** 2028-05-12
- **Final completion:** 2028-05-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06147037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06147037, "A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06147037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*